Pharvaris (PHVS) Non Operating Income (2021 - 2026)
Pharvaris (PHVS) posted Non Operating Income of $6.3 million for Q1 2026, down 100.0% on a QoQ basis from $6925.9 billion in Q3 2025, and up 254.43% year-over-year from $1.8 million in Q1 2025.
Pharvaris (PHVS) Non Operating Income (2021 - 2026) Analysis & Trends
Pharvaris' Non Operating Income history runs 6 years deep, the most recent figure standing at $6.3 million for Q1 2026.
- Quarterly Non Operating Income rose 254.43% year-over-year to $6.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10749.8 billion (up 10239.67% YoY) and the FY2025 annual result came in at -$4.4 million, down 130.54% from the prior year.
- Non Operating Income was $6.3 million for Q1 2026 at Pharvaris, down from $6925.9 billion in the prior quarter.
- Across five years, Non Operating Income topped out at $6925.9 billion in Q3 2025 and bottomed at -$3929.9 billion in Q3 2024.
- A 5-year average of $454.7 billion and a median of $3.0 million in 2023 frame the typical range for Non Operating Income.
- Peak annual rise in Non Operating Income reached 168404778.33% in 2024, while the deepest fall reached 131324989.28% in 2024.
- Pharvaris' Non Operating Income stood at -$26.9 million in 2022, then jumped by 91.55% to -$2.3 million in 2023, then soared by 168404778.33% to $3823.8 billion in 2024, then jumped by 81.12% to $6925.9 billion in 2025, then slumped by 100.0% to $6.3 million in 2026.
- Business Quant data shows PHVS's Non Operating Income at $6.3 million in Q1 2026, $6925.9 billion in Q3 2025, and -$4.1 million in Q1 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -9.22 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 444,000.00 |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 188.30 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | 5.75 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -8.59 Mn |
| 10 | Pharvaris | 2.22 Bn | 1.94 Bn | - | 6.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.26 Mn |
| Sep 30, 2025 | 6,925.94 Bn |
| Mar 31, 2025 | -4.05 Mn |
| Dec 31, 2024 | 3,823.84 Bn |
| Sep 30, 2024 | -3,929.86 Bn |
| Jun 30, 2024 | 5.08 Mn |
| Mar 31, 2024 | 628,156.10 |
| Dec 31, 2023 | -2.27 Mn |
| Sep 30, 2023 | 2.99 Mn |
| Jun 30, 2023 | 709,619.36 |
| Mar 31, 2023 | -1.60 Mn |
| Dec 31, 2022 | -26.88 Mn |
| Sep 30, 2022 | 11.59 Mn |
| Jun 30, 2022 | 12.27 Mn |
| Mar 31, 2022 | 3.81 Mn |
| Dec 31, 2021 | -8,692.92 Bn |
| Sep 30, 2021 | 5.02 Mn |
| Jun 30, 2021 | -2.98 Mn |
| Mar 31, 2021 | 7.02 Mn |